New hope for Tough-to-Treat breast cancer: two drugs vs. one
NCT ID NCT07222215
Summary
This study is testing if combining two drugs, capecitabine and elacestrant, works better than just capecitabine alone for people with advanced, hormone-sensitive breast cancer. It's for patients whose cancer has stopped responding to a common class of prior medications. The main goal is to see if the combination can keep the cancer from growing for a longer time, especially for those with a specific genetic change (ESR1 mutation).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.